Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $6
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5.5 to $6.
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5.5 to $6.